The company held two huge scientific conferences, first at the historic Abdeen Palace in Cairo, and second at Opera house in Alexandria attended by more than 1000 doctors, headed by Professors of Gastroenterology and Endoscopy from different Egyptian universities.
The conferences highlighted FDA approval of Vonoprazan (a novel potassium-competitive acid blocker P-CABs) in two combinations to treat Helicobacter pylori infection, which typically affects the stomach or the small intestine, as Vonoprazan provides more profound and durable gastric acid suppression than traditional [proton pump inhibitors (PPIs)] that, when used empirically, translate into higher eradication rates than PPI-based triple therapy and, Vonoprazon, is also effective in the eradication of clarithromycin-resistant H. pylori strains. Vonoprazan has been clinically used for the short-term treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease and Helicobacter pylori (H. pylori) infection in Japan. The healing rate of GERD and gastric ulcers by vonoprazan is more than 95 and 90%, respectively; also, it is effective in curing PPI-resistant GERD.
“Zeta Pharma continues its leadership in offering the Egyptian’s patient the latest treatment that provide solutions to unmet needs in different therapeutic areas” said Dr.Faris Salma Business Development manager at Zeta Pharma.
Moreover, it is worth mentioning that Zeta Pharma is the market leader in Gastroesophageal reflux disease with its generic product, Nexicure MUPS (Esomeprazole).
As per its commitment to offer the latest treatment for the Egyptian’s patients., in Jan 2022 Zeta Pharma was the first Egyptian pharmaceutical company to introduce two concentrations of 10mg and 20 mg of vonoprazan in the Egyptian market through its brand Vonseca®
About Vonoprazan & P-CABs
Vonoprazan is a first-in-class potassium-competitive acid blocker. It was approved in the Japanese market in February 2015.
Vonoprazan is used in form of the fumarate for the treatment of gastroduodenal ulcer (including some drug-induced peptic ulcers) and reflux esophagitis and can be combined with antibiotics for the eradication of Helicobacter pylori.